PT-141
Reviewed by Fat Man in the Arena · Updated March 2026
Key Takeaway
PT-141 (Bremelanotide) is FDA-approved for hypoactive sexual desire disorder in women. It works through the melanocortin system rather than the vascular system like Viagra.
How it works
Activates melanocortin-4 receptors in the brain to increase sexual desire through central nervous system pathways.
Benefits
- FDA-approved for HSDD in women
- Works through desire pathway (not vascular)
- Effective in both men and women
Side effects
- Nausea (most common)
- Flushing
- Headache
- Skin darkening
Dosing protocol
Typical Dose
1.75 mg per use
Frequency
As needed, at least 45 min before activity
FDA-approved as Vyleesi. Max 8 doses per month.
FDA status
FDA Approved for: Hypoactive sexual desire disorder in premenopausal women (Vyleesi)
Goals
Related peptides
Looking for weight loss peptides? See our complete guide to the best peptides for weight loss or compare semaglutide vs tirzepatide.
Weekly peptide research updates
New studies, GLP-1 news, protocol insights, and weight loss data — delivered every week. Free. No spam.
Medical Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional medical consultation, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol.